Uses of Epocassa

Epocassa is a drug that works on blood, prepared in the form of an injectable solution with the main ingredient Erythropoietin. Epocassa drug is used to treat anemia in patients with chronic kidney failure, cancer, HIV...

Epocassa contains recombinant erythropoietin and is packaged as a solution for injection - 2000IU content. Erythropoietin itself is an essential hormone for red blood cell formation, most of which is produced by the kidneys, acting in response to tissue hypoxia. The remaining small part (10-14%) is synthesized by the liver (the main organ that produces erythropoietin is located in the fetus). Erythropoietin acts as a growth factor and stimulates mitotic activity of erythroid stem cells and erythrocyte early progenitor cells. This hormone also has a differentiating effect and stimulates the transformation of the erythrocyte colony-forming unit (CFU) into pro-erythroblasts. Therefore, Epocassa is effective in treating anemia in some diseases.
With drug activities, Epocassa is indicated for use in the following cases:
Treatment of anemia associated with chronic kidney failure, including patients on dialysis (end-stage renal disease) and not on dialysis. . Epocassa is indicated to increase and maintain red blood cell levels (expressed as hematocrit or hemoglobin) and reduce the need for transfusion. Non-dialysis patients with symptoms of anemia are considered for use (if hematocrit is less than 10g/dL). Anemia in people with HIV and treated with zidovudine. Anemia due to chemotherapy use in cancer patients. Reduce blood transfusion in patients undergoing surgery. Anemia in premature babies. Doctors recommend contraindicated use of Epocassa for people:
Have uncontrolled high blood pressure. There is a history of hypersensitivity to human albumin or other components of the drug. There is a history of hypersensitivity to preparations derived from mammalian cells.

How to use: Epocassa medicine in the form of an injection solution should be administered by intravenous injection or subcutaneous injection.
Dosage:
Adults on chronic dialysis: 50 IU/kg/time x 3 times/week intravenously or 40 IU/kg/time x 3 times/week injected subcutaneously. Patients who do not need dialysis: Inject dose of 75-100 IU/kg/week. HIV-infected patients and taking zidovudine: The dose is 100 IU/kg x 3 times/week intravenously or subcutaneously, the maximum dose is 300 IU/kg x 3 times/week. Cancer patients undergoing chemotherapy: 150 IU/kg x 3 times/week subcutaneously. Blood transfusion for patients before surgery: 300 IU/kg/day subcutaneously x 10 days before surgery. Anemia in preterm neonates: 250 IU/kg x 3 times/week by subcutaneous injection from the 2nd week postpartum and 8 weeks thereafter.

Some unwanted effects that patients using Epocassa may encounter such as:
Headache; Athritis; Tired; Nausea; Diarrhea . Note: If you see any other symptoms that are suspected to be caused by using Epocassa, you should immediately notify your doctor for timely indications.

Use caution in patients with convulsive events. Although there are currently no experimental studies in pregnant and lactating women, Epocassa should only be used when the benefits outweigh the risks. There is currently no information on Epocassa drug interactions. However, still inform your doctor about the medication you are taking to avoid drug interactions and have the right dose.
Hopefully with the sharing of Epocassa medicine will help the treatment and use process in patients be safest. If you have any questions, you should contact your doctor directly for the appropriate appointment.